Project Grant R01CA299200
Award Date 5/1/26
Completion Date 4/30/31
Dollars Obligated $416K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02111, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute awarded $1.22M to the University of Massachusetts Boston under its Cancer Biology Research program (CFDA 93.396) effective August 1, 2025, through July 31, 2028. This project grant supports fundamental research to advance understanding of extracellular vesicles (EVs)—cell-derived, membrane-bound structures that carry biomolecules and serve as circulating biomarkers for disease diagnosis and therapeutic delivery. The research...
- Federal Grant Award Summary Tufts University School of Medicine received a $883,825.75 Project Grant award from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) on May 15, 2025. This research initiative leverages existing leukocyte deoxyribonucleic acid (DNA) methylation data to identify biological pathways linking obesity to 13 distinct cancer types. The project utilizes data from the Atherosclerosis Risk in Communities Study (ARIC) to...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $237,023 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Harvard Medical School, effective March 13, 2026 through February 28, 2029. This award supports the development of high-throughput technological tools designed to track the fate of prematurely terminated transcripts in cancer cells. Specifically, the research focuses on alternative polyadenylation (APA) events—post-transcriptional gene...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Emory University a $156,500 Project Grant on August 1, 2025, under the Cancer Treatment Research program (CFDA 93.395) to conduct integrated multi-omics research exploring the pathophysiology of cachexia in head and neck squamous cell carcinoma (HNSCC) patients. The two-year project, concluding July 31, 2027, will investigate the systemic biological mechanisms underlying cancer cachexia through comprehensive analysis of...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a Project Grant totaling $162,080 under the Cancer Research Manpower program (CFDA 93.398) on December 27, 2025, with a completion date of June 30, 2028. Dr. Komatsu's laboratory is conducting research to visualize and characterize B cell infiltration and aggregation within the tumor microenvironment, with particular focus on the role of high endothelial venules (HEVs) as critical gateways for...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $431,970 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) for the period April 1, 2026 through March 31, 2028. The research project investigates dual-targeting therapeutic approaches for acute myeloid leukemia (AML) by combining BCL-2 (B-cell lymphoma-2) inhibition with CD123-directed natural killer (NK) cell engager immunotherapies. The research...
- Federal Project Grant Award Summary Albert Einstein College of Medicine received a $442,816 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded April 2, 2026, with completion targeted for March 31, 2027. This award funds research interrogating erythroid differentiation and the BCL-XL axis in TP53-mutated acute myeloid leukemia (AML). The project addresses a critical clinical gap by investigating how TP53-mutated AML patients...
- Federal Grant Award Summary Boston University received a $184,036 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) effective July 1, 2025, through February 29, 2028. The award supports the development and optimization of disulfated polyamidosaccharide nanoparticles as a targeted chemotherapeutic delivery system, specifically designed to target P-selectin (CD62P) protein on tumor cells. This research addresses the critical challenge...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $692,197 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) for the period May 1, 2026 through April 30, 2031. The award funds research and development of MTAP (Methylthioadenosine Phosphorylase) transition state analog inhibitors designed to enable synthetic-lethal cancer therapy approaches. The project delivers novel, highly specific MTAP inhibitor compounds and...